Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 31
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Redhill Biopharma Ltd
RDHL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.3878
-0.0288
-6.91%
Últ. Act.: Oct 30, 4:37 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Redhill Biopharma Financials
Redhill Biopharma (RDHL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Redhill Biopharma (NASDAQ:RDHL) reported H1 2026 EPS $0.00 And Revenue $0.00.
Benzinga Newsdesk
PRO
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
Benzinga Newsdesk
PRO
Redhill Biopharma H1 Sales $4.079M Up From $2.572M YoY
Redhill Biopharma (NASDAQ:RDHL) reported $4.079 million in sales this quarter. This is a 58.59 percent increase over sales of $2.572 million the same period last year.
Benzinga Newsdesk
PRO
Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly losses of $(0.02) per share. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $8.04 million in sales
Benzinga Newsdesk
PRO
Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY
Benzinga Newsdesk
Crude Oil Moves Lower; Moderna Shares Plunge
Avi Kapoor
